Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048368 | 0.94 | TSHR (0.56) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3503182 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11835881 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11830417 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11823526 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11830603 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11826116 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11830731 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11830919 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11824923 | 0.92 | TSHR (0.54) | TSHRALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912333-A | Synthesis method of methyl 4-aldehyde butyrate | 安徽乐雍生物科技有限公司 | 2025-05-02 | — | — | CN | claimed |
| US-10364300-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2019-07-30 | — | — | US | claimed |
| CN-107567464-A | For the method for the polydiene and polydiene copolymer that produce cold flow properties reduction | 株式会社普利司通 | 2018-01-09 | — | — | CN | claimed |
| US-20170247478-A1 | Method For Producing Polydienes And Polydiene Copolymers With Reduced Cold Flow | BRIDGESTONE CORPORATION (JP) | 2017-08-31 | — | — | US | claimed |
| EP-3204429-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | Bridgestone Corporation (JP) | 2017-08-16 | — | — | EP | claimed |
| CN-103232356-B | Technology for preparing 3-phenyl-4-aminobutyric acid hydrochloride | 天津金族科技有限公司 | 2017-02-15 | — | — | CN | claimed |
| WO-2016057388-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2016-04-14 | — | — | WO | claimed |
| CN-104311424-A | Optically pure beta-nitroalcohol derivatives and synthesis method thereof | JINGCHU UNIVERSITY OF TECHNOLOGY | 2015-01-28 | — | — | CN | claimed |
| CN-104292062-A | Method for catalyzing and synthesizing optically pure beta-nitramine derivative | JINGCHU UNIVERSITY OF TECHNOLOGY | 2015-01-21 | — | — | CN | claimed |
| US-20260109684-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4662205-A1 | DERIVATIVES, IMMUNOGENS, AND ANTIBODIES AND USE OF THE SAME IN DETECTION OF ECSTASY-CLASS COMPOUNDS | Siemens Healthcare Diagnostics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025245351-A1 | SUBSTITUTED ARYL SULFONAMIDES AND COMPOSITIONS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-11-27 | — | — | WO | disclosed |
| EP-4131548-B1 | NON-AQUEOUS ELECTROLYTE FOR BATTERY, PRECURSOR FOR LITHIUM SECONDARY BATTERY, METHOD FOR MANUFACTURING LITHIUM SECONDARY BATTERY, LITHIUM SECONDARY BATTERY, PHOSPHAZENE COMPOUND, AND ADDITIVE FOR BATTERY | MITSUI CHEMICALS INC (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-4594303-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | New York University (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-1993021181-A1 | AZACYCLIC COMPOUNDS | MERCK SHARP & DOHME LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993004040-A1 | AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK SHARP & DOHME LIMITED (GB) | 1993-03-04 | — | — | WO | disclosed |
| EP-0528495-A1 | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them | MERCK SHARP & DOHME LTD. (GB) | 1993-02-24 | — | — | EP | disclosed |
| WO-1993000331-A1 | FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES | PFIZER INC. (US) | 1993-01-07 | — | — | WO | disclosed |
| US-4677114-A | REDUCING AMNESIA, TREATMENT OF SENILITY | WARNER-LAMBERT COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| US-4677098-A | REDUCING AMNESIA AND TREATING SENILITY | WARNER-LAMBERT COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109684-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | AGER, GLP1R, HMGB1 | TSHR 2243/4885ALDH1A1 1294/4885LMNA 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.